After the administration of Simeglutide it is generally necessary to watch for gastrointestinal reactions, acute pancreatitis and C-cell carcinoma of the thyroid. As a human glucagon-like peptide-1 analog, it is indicated for glycemic control in adults with type 2 diabetes mellitus and may reduce the risk of adverse cardiovascular events in this population. 1. Gastrointestinal Reactions: The use of GLP-1 receptor agonists may be associated with adverse gastrointestinal reactions. This should be considered when treating patients with renal impairment, as nausea, vomiting and diarrhea may lead to dehydration, which may lead to deterioration of renal function. 2. Acute Pancreatitis: Patients should be informed of the characteristic symptoms of acute pancreatitis prior to administration and the product should be discontinued if pancreatitis is suspected. If the diagnosis of pancreatitis is confirmed, the product should not be used for treatment, and patients with a history of pancreatitis should use the product with caution. 3. Risk of thyroid C-cell tumors: At clinically relevant plasma exposure levels of selegiline, it causes a dose-dependent and treatment duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas). Of course, it is not suitable for all diabetic patients, and should be contraindicated if there is a personal history of medullary thyroid carcinoma and type 2 multiple endocrine neoplasia, and any discomfort after the shot of simepaglutide should go to the hospital in a timely manner.